Tuberculosis and Leprosy Coinfection: A Perspective on Diagnosis and Treatment

Lisa Mangum,1 Dustin Kilpatrick,2 Barbara Styrjewska,3 and Rahul Sampath4

1Infectious Disease and 2Internal Medicine, Carolinas Healthcare System Blue Ridge, Morganton, North Carolina; 3Chief Clinical Branch, National Hansen’s Institute, Baton Rouge, Louisiana; 4Infectious Disease, Carolinas Healthcare System Blue Ridge, Morganton, North Carolina

Both leprosy and tuberculosis (TB) are known to have similar geographic endemicity. In the setting of coinfection, interferon-gamma release assays (IGRAs) to detect latent TB can be falsely positive. We report a case of leprosy with a positive IGRA and asymptomatic active pulmonary TB. Minocycline and dapsone therapy was initiated during the workup for TB and changed to rifampin (Rif), isoniazid, pyrazinamide, and ethambutol, with the addition of dapsone once coinfection was confirmed. Our review of the literature revealed a preponderance of coinfection reported with borderline and lepromatous disease. Ten patients were diagnosed with leprosy as the first infection; 7 of these patients (70%) were treated with Rif before TB diagnosis, and 70% (7/10) of coinfected patients were on steroids. If treatment for leprosy is a consideration before ruling out active TB, then minocycline may temporarily replace the Rif. The dire implications of Rif monotherapy in undiagnosed coinfection may warrant chest radiography with or without sputum microbiology as routine initial workup for all leprosy cases.

Keywords. coinfection; leprosy; resistance; steroids; tuberculosis.

Both leprosy and tuberculosis (TB) are known to have similar geographic endemicity [1, 2], and TB needs to be ruled out in cases of leprosy before treatment is initiated with rifampin (Rif)-based regimens. The use of protein-based interferon-gamma release assays (IGRAs) to test for latent TB is confounded by the cross-reactivity of T-cell response with the protein homologs in Mycobacterium leprae [3, 4]. The Purified Protein Derivative (PPD) skin test may have some utility in the diagnosis of latent TB in the setting of paucibacillary leprosy (PBL); however, “giant reactions” to PPD testing have been documented in mono-infection with multibacillary leprosy (MBL) [5, 6].

CASE REPORT

A 32-year-old Marshallese woman presented with osteomyelitis of the left third distal phalanx, multiple burn wounds on both hands (Figure 1), and hypopigmented skin lesions (Figure 2) with reduced thermal sensation for several months. A limited disarticulation of the distal phalanx and slit skin smears of hypopigmented skin were performed at the National Hansen’s Institute. The smears were Fite stain negative for acid fast bacilli (AFB); however, polymerase chain reaction (PCR) was positive for M. leprae. Initial TB workup showed a positive IGRA and PPD skin test greater than 15 mm, and chest radiography (CXR) showed a subtle infiltrate in the right middle lobe, raising suspicion for active TB despite lack of respiratory symptoms. The patient’s sputum was AFB smear negative but culture positive for drug-susceptible TB. During the above workup for TB, minocycline and dapsone therapy was initiated for 2 months and was changed to Rif, isoniazid (INH), pyrazinamide, ethambutol (RIPE therapy) with the addition of dapsone once sputum cultures were reported. Repeat sputum cultures after 1 month of RIPE therapy were negative for TB, and RIPE therapy was consolidated to INH and Rif after 2 months. INH, Rif, and dapsone were continued for 4 months, after which the patient was considered effectively treated for TB. The patient was then placed back on minocycline and dapsone for an additional 4 months, completing a 1-year treatment course for leprosy. One month into therapy, CXR was normal, and at the completion of therapy, she had improvement in skin lesions and overall sense of well-being. The patient did not experience any immunological reactions during the above therapy.

DISCUSSION

In the past 15 years, 13 cases of TB and leprosy coinfection have been published; they are summarized in the Table 1. A preponderance of coinfection was seen with borderline and lepromatous disease cases. The immunological milieu of the host appears to paradoxically influence susceptibility to mycobacterial
coinfection, with no consensus regarding whether prior exposure to one offers protection or predisposition to the other. On one end of the spectrum, impaired cell-mediated immunity [7, 8] in patients with MBL may predispose to TB coinfection, whereas among immunocompetent contacts of patients with Hansen’s disease in Brazil, the presence of a Bacillus Calmette-Guerin vaccination scar offered 98% protection against MBL [9].

From a treatment perspective, the US Department of Health and Human Services recommends daily Rif [10] in combination with other drugs for the treatment of leprosy across the spectrum. An undiagnosed coinfected patient runs the risk of receiving Rif monotherapy and developing resistance during therapy [11]. In our review, 10 patients were diagnosed with leprosy as the first infection, and of these 10, 7 patients (70%) were treated with Rif before diagnosing TB. Seven of the 10 patients (70%) mentioned above were on steroids before the diagnosis of TB, suggesting that steroids may be a risk factor for reactivation of TB. However, in the TRIPOD studies, no incidence of TB was seen among 300 patients over 24 months who were on prednisone and multidrug therapy for Hansens [12].

CONCLUSION

The clinical implications of failure to identify coinfection cannot be understated, and a positive IGRA or PPD test in a patient with Leprosy should not be considered false positive without ruling out active TB. Rif is a vital component in the treatment regimen for both TB and leprosy, and if treatment for leprosy is a consideration before ruling out active TB, then minocycline may temporarily replace Rif. The dire implications of Rif monotherapy in undiagnosed TB and leprosy coinfection may warrant a CXR with or without sputum microbiology as routine initial workup for all leprosy cases. Additionally, steroid use may be a risk factor for coinfection.
### Table 1. Summary of reported cases for coinfection of Leprosy and Tuberculosis within last 15 years

| Year/Author | Age | Sex | Type of Leprosy | First Infection/TX Given for Leprosy | Gap of Dx of TB | Type of TB | X-Ray/PPD/Interferon | Sputum | Dx of Leprosy | Risk Factors | Lepra Rxn |
|-------------|-----|-----|----------------|--------------------------------------|----------------|------------|----------------------|---------|--------------|-------------|----------|
| 2003/Lee et al. [13] | 62-M | M | BL | TB | 6 mo | NA | Pulm | CXR abnormal | AFB+ | Histochem-Fite-Farco, slit skin smear | NA | Type I |
| 2007/Seeramareddy et al. Case #1 [14] | 65-M | M | LL | Leprosy/Dapsone Clofazimine Rifampin | 3 mo | No | Pulm | Pleural effusions, CXR w/ infiltrate | AFB+ | NA | Steroid | No |
| 2007/Seeramareddy et al. Case #2 [14] | 50-M | M | LL | Leprosy/Thailomide Clofazimine Prednisone | 22 mo | NA | Pulm & Perit | CXR cavitory lesions | AFB+ | NA | Steroid | Type II |
| 2010/Prasid et al. [15] | 34-M | M | BL | Leprosy/ Dapsone Clofazimine Rifampin | 11 mo | No | Pulm | CXR, cavitory lesions, PPD 22 mm | AFB+ | Slit skin smear | Steroid | Type II |
| 2013/Trindale et al. Case #1 [16] | 31-M | M | BB-BT | TB | 6 mo | NA | Pleural | PPD 14 mm, pleural effusion, CXR abnormal | NA | Histochem-Fite-Farco stain | NA | Type I |
| 2013/Trindale et al. Case #2 [16] | 46-F | F | BB-BT | Leprosy/Thailomide Clofazimine Prednisone | 1 mo | NA | Pulm | PPD 10 mm, CT chest opacities | AFB+ | Histochem with anti-BCG | NA | Steroid | Type I |
| 2014/Choubey et al. [17] | 34-M | M | LL | TB | ½ mo | No | Pulm | CXR w/ patchy infiltrates | AFB+ | Slit skin smear | NA | NA |
| 2014/Rawson et al. [18] Case #1 | 18-M | M | LL | Leprosy/Dapsone Clofazimine Rifampin | 9 mo | No | Pulm | NA | AFB+ | Slit skin smear | Steroid | Silent Neuritis |
| 2014/Rawson et al. [18] Case #2 | 38-M | M | LL | Leprosy/Dapsone Clofazimine Rifampin | 3 y | No | Extra-Pulm (CNS) | NA | PCR | Slit skin smear | Steroid | Type II |
| 2014/Rawson et al. [18] Case #3 | 46-M | M | LL | Leprosy/Dapsone Clofazimine Rifampin | 11 mo | No | Pulm | NA | AFB+ | Slit skin smear | No | No |
| 2015/Sendrasoa et al. [19] | 49-M | M | LL | Leprosy/Dapsone Clofazimine Rifampin | 17 mo | No | Pulm | CT chest opacities | AFB+ | Histochem- slit skin smear, PCR biopsy | Steroid | Type II |
| 2015/Verma et al. [20] | 38-M | M | BL | Leprosy/Dapsone Clofazimine Rifampin | 7 mo | No | Pulm | CXR cavitory lesions | AFB+ | Skin smear | NA | Type II |
| 2017/present author | 33-F | F | TL | Leprosy/Minocycline Dapsone | 2 mo | No | Pulm | CXR opacities, Interferon Gold positive | AFB+ | PCR biopsy | NA | No |

Abbreviations: AFB, Acid Fast Bacilli; BB-BT, mid-borderline/borderline tuberculoid leprosy; BL, lepromatous borderline leprosy; CNS, central nervous system; CXR, chest radiography; LL, lepromatous leprosy; Mino, minocycline; NA, data not available; Neuro, neuritis; PCR, polymerase chain reaction; Perit, peritoneal; PPD, purified protein derivate; Pulm, pulmonary; TB, tuberculosis; TL, tuberculoid leprosy.
Acknowledgments

Potential conflicts of interest. No authors contributing to the publication of this paper have any conflicts of interest or funding sources to report. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. World Health Organization. Estimated tuberculosis (TB) cases and deaths 200–WHO, 2016. Available at: http://gamapserver.who.int/gho/interactive_charts/tb/cases/atlas.html. Accessed 29 January 2018.
2. World Health Organization. Global leprosy programme. Available at: http://www.searo.who.int/entity/global_leprosy_programme/epidemiology/en/. Accessed 29 January 2018. Published by WHO in 2016.
3. Geluk A, van Meijgaarden KE, Franken KL, et al. Identification and characterization of the ESAT-6 homologue of Mycobacterium leprae and T-cell cross-reactivity with Mycobacterium tuberculosis. Infect Immun 2002; 70:2544–8.
4. Geluk A, van Meijgaarden KE, Franken KL, et al. Immunological crossreactivity of the Mycobacterium leprae CFP-10 with its homologue in Mycobacterium tuberculosis. Scand J Immunol 2004; 59:66–70.
5. Sampaio EP, Duppre NC, Nery JA, et al. Development of giant reaction in response to PPD skin test in lepromatous leprosy patients. Int J Lepr Other Mycobact Dis 1993; 61:205–13.
6. Waters MF, Stanford JL. Giant reactions to tuberculin in lepromatous leprosy patients. Int J Lepr Other Mycobact Dis 1985; 53:546–53.
7. Nigam P, Dubey AL, Dyal SG, et al. The association of leprosy and pulmonary tuberculosis. Lepr India 1979; 51:65–73.
8. Hasan Z, Jamil B, Zaidi I, et al. Elevated serum CCL2 concomitant with a reduced mycobacterium-induced response leads to disease dissemination in leprosy. Scand J Immunol 2006; 63:241–7.
9. Goulart JM, Bernardes Souza DO, Marques CR, et al. Risk and protective factors for leprosy development determined by epidemiological surveillance of household contacts. Clin Vaccine Immunol 2008; 15:101–5.
10. US Health Resources and Services Administration. Recommended treatment regimens for Hansen’s. Available at: https://wwwchrsa.gov/hansens-disease/diagnosis/recommended-treatment.html. Accessed 29 January 2018.
11. Lipsitch M, Levin BR. Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance. Int J Tuberc Lung Dis 1998; 2:187–99.
12. Richards JH, Withington SG, Anderson AM, et al. Adverse events of standardized regimens of corticosteroids for prophylaxis and treatment of nerve function impairment in leprosy: results from the ‘TRIPOD’ trials. Lepr Rev 2003; 74:319–27.
13. Lee, H.N., et al. Concomitant pulmonary tuberculosis and leprosy. J Am Acad Dermatol 2003; 49:755–757.
14. Sreramararieddy CT, Meneses RG, Kishore P. Concomitant age old infections of mankind - tuberculosis and leprosy: a case report. J Med Case Rep 2007; 1:43.
15. Prasad R, Verma SK, Singh R, Hosmane G. Concomitant pulmonary tuberculosis and borderline leprosy with type-II lepra reaction in single patient. Lung India 2010; 27:19–23.
16. Trindade MÁ, Miyamoto D, Benard G, et al. Leprosy and tuberculosis co-infection: clinical and immunological report of two cases and review of the literature. Am J Trop Med Hyg 2013; 88:236–40.
17. Choubey, S, Sharma M, Agrawal B. Pulmonary tuberculosis and lepromatous leprosy co-infection in a single individual: a case report. J Assoc Chest Physicians 2014; 2:40.
18. Rawson TM, Anjum V, Hodgson J, et al. Leprosy and tuberculosis concomitant infection: a poorly understood, age-old relationship. Lepr Rev 2014; 85:288–95.
19. Sendrasoa FA, Ranaivo JM, Raharolahy O, et al. Pulmonary tuberculosis and lepromatous leprosy coinfection. Case Rep Dermatol Med 2015; 2015:898410.
20. Verma, A.K., et al. Coexistence of leprosy and pulmonary tuberculosis: an uncommon entity. Med J DY Patil Univ 2015; 8:675.